• Aliases: CMA-676; CDP-771; calicheamicin-conjugated humanized anti-CD33 monoclonal antibody
    • A mAb to CD33 antigen, which is expressed on leukemic blast cells in 80% of acute myelogenous leukemia patients.
    • Unlabeled and investigational use in relapse/refractory acute myelogenous leukemia and acute promyelocytic leukemia (In 2010, gemtuzumab was pulled out from the US market because of safety concerns for new patients.)
    • Recommended dose: 9 mg/m2 IV over 2 hours for 2 doses, with at least 14 to 28 days in between doses
    • Half-life: 41 to 45 hours for initial dose; repeat dose: 60 to r repeat dose (total calicheamicin); 100 to 143 hours (unconjugated)
    Other topics in Targeted and Immunotherapy Agents